Evidence map›Paper›PMID 41894075›Full record

ReviewMolecular biology reports2026

Therapeutic potential of sulforaphane in neurodegenerative diseases: mechanistic Insights into Nrf2, NF-κB, TrkB, SIRT1, MAPK, and JAK/STAT signalling pathways.

Omkar Kumar Kuwar, Sandip Tejpal, Vipul Sharma, Akash Sharma, Aayush Rao, Mayank Attri, Pallavi, Mamta Sachdeva Dhingra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Omkar Kumar KuwarDepartment of Pharmacology, Bihar College of Pharmacy, New Bailey Road, Patna, 801503, Bihar, India. omkar.official.955@gmail.com.ORCID http://orcid.org/0009-0007-1796-4913
Sandip TejpalDepartment of Pharmaceutical Sciences, Guru Nanak Dev University, 143005, Punjab, Amritsar, India.
Vipul SharmaMotherhood University, Roorkee-Dehradun Road, Haridwar, Uttarakhand, 247661, India.
Akash SharmaDepartment of Pharmacy, Global Group of Institutes, Amritsar, 143501, Punjab, India.
Aayush RaoDepartment of Pharmacy, Global Group of Institutes, Amritsar, 143501, Punjab, India.
Mayank AttriDepartment of Pharmacy, Global Group of Institutes, Amritsar, 143501, Punjab, India.
PallaviAmity Institute of Pharmacy, Amity University, Jaipur, Rajasthan, India.
Mamta Sachdeva DhingraDepartment of Pharmacology, Bihar College of Pharmacy, New Bailey Road, Patna, 801503, Bihar, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis, are chronic and progressive disorders distinguished by neuronal dysfunction, oxidative stress, neuroinflammation, and abnormal protein aggregation. Due to the multifactorial nature of these disorders, current pharmacotherapies provide limited symptomatic relief without altering disease progression. Sulforaphane, a naturally occurring isothiocyanate abundant in cruciferous vegetables like broccoli, has emerged as a potent neuroprotective compound owing to its pleiotropic effects on key cellular signalling pathways. This review provides a thorough overview of the mechanistic insights underlying SFN’s neuroprotective potential, with a focus on the modulation of key signalling pathways such as Nrf2/ARE, NFĸB, BDNF/TrkB, SIRT1, MAPK, and JAK/STAT. Through the activation of antioxidant defenses and suppression of inflammatory cascades, SFN effectively mitigates neuronal damage and supports cellular homeostasis. Preclinical studies consistently demonstrate SFN’s ability to attenuate oxidative stress, inhibit apoptosis, preserve mitochondrial function, and improve neurobehavioral outcomes. While limited clinical evidence supports its safety and bioactivity, further investigations are needed to establish its therapeutic utility in human populations. Overall, SFN represents a promising natural compound with significant potential for the prevention and management of neurodegenerative diseases through multi-targeted pathway modulation.

Indexed as

IsothiocyanatesNeurodegenerative DiseasesSulfoxidesAnimalsHumansJanus KinasesNeuroprotective AgentsNF-E2-Related Factor 2NF-kappa BOxidative StressReceptor, trkBSignal TransductionSirtuin 1STAT Transcription FactorsIsothiocyanatesJanus KinasesNeuroprotective AgentsNFE2L2 protein, humanNF-E2-Related Factor 2NF-kappa BReceptor, trkBSIRT1 protein, humanSirtuin 1STAT Transcription FactorssulforaphaneSulfoxidesJAK/STATMAPKNeurodegenerationNeuroinflammationNFĸBNrf2Oxidative stressSIRT1SulforaphaneTrkB

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.